Andrew Reardon - 23 Sep 2024 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Signature
/s/ Andrew Reardon
Issuer symbol
LGND
Transactions as of
23 Sep 2024
Net transactions value
-$94,661
Form type
4
Filing time
25 Sep 2024, 20:54:39 UTC
Previous filing
30 Aug 2024
Next filing
19 Feb 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Options Exercise $104,540 +2,000 +8.9% $52.27 24,534 23 Sep 2024 Direct
transaction LGND Common Stock Sale $199,201 -2,000 -8.2% $99.60 22,534 23 Sep 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Employee Stock Option (right to buy) Options Exercise $0 -2,000 -2.7% $0.000000 70,944 23 Sep 2024 Common Stock 2,000 $52.27 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter.